Abstract
With the emergence of multi-drug resistant (MDR) and extensively drug resistant (XDR) Mycobacterium tuberculosis (Mtb), new classes of anti-mycobacterial agents with very different modes of action compared to classical antibiotics, are urgently needed. In this study, a series of 26-residue, amphipathic α-helical antimicrobial peptides consisting of all D-amino acid residues and synthetic human L-LL37 (L-enantiomer) and D-LL37 (D-enantiomer) were investigated against M. tuberculosis susceptible strain (H37Rv) and a clinical multi-drug resistant strain (Vertulo). Minimal inhibitory concentrations (MICs) were determined through a peptide killing assay. D5, the most active analog against M. tuberculosis had a MIC value of 11.2 μM (35.2 μg/ml) against H37Rv strain and 15.6 μM (49 μg/ml) against the MDR strain. Peptide D1 had similar activity as D5 against the MDR strain (57 μg/mL), a 9-fold improvement in hemolytic activity and a 7.4-fold better therapeutic index compared to D5. Surprisingly, LL37 enantiomers showed little to no activity compared to the de-novo designed α-helical antimicrobial peptides.
Keywords: Antimicrobial peptides, Mycobacterium tuberculosis, hemolysis, all D-enantiomerAntimicrobial peptides, Mycobacterium tuberculosis, hemolysis, all D-enantiomer
Protein & Peptide Letters
Title: Anti-Tuberculosis Activity of α-Helical Antimicrobial Peptides: De Novo Designed L- and D-Enantiomers Versus L- and D-LL37
Volume: 18 Issue: 3
Author(s): Ziqing Jiang, Michael P. Higgins, James Whitehurst, Kevin O. Kisich, Martin I. Voskuil and Robert S. Hodges
Affiliation:
Keywords: Antimicrobial peptides, Mycobacterium tuberculosis, hemolysis, all D-enantiomerAntimicrobial peptides, Mycobacterium tuberculosis, hemolysis, all D-enantiomer
Abstract: With the emergence of multi-drug resistant (MDR) and extensively drug resistant (XDR) Mycobacterium tuberculosis (Mtb), new classes of anti-mycobacterial agents with very different modes of action compared to classical antibiotics, are urgently needed. In this study, a series of 26-residue, amphipathic α-helical antimicrobial peptides consisting of all D-amino acid residues and synthetic human L-LL37 (L-enantiomer) and D-LL37 (D-enantiomer) were investigated against M. tuberculosis susceptible strain (H37Rv) and a clinical multi-drug resistant strain (Vertulo). Minimal inhibitory concentrations (MICs) were determined through a peptide killing assay. D5, the most active analog against M. tuberculosis had a MIC value of 11.2 μM (35.2 μg/ml) against H37Rv strain and 15.6 μM (49 μg/ml) against the MDR strain. Peptide D1 had similar activity as D5 against the MDR strain (57 μg/mL), a 9-fold improvement in hemolytic activity and a 7.4-fold better therapeutic index compared to D5. Surprisingly, LL37 enantiomers showed little to no activity compared to the de-novo designed α-helical antimicrobial peptides.
Export Options
About this article
Cite this article as:
Jiang Ziqing, P. Higgins Michael, Whitehurst James, O. Kisich Kevin, I. Voskuil Martin and S. Hodges Robert, Anti-Tuberculosis Activity of α-Helical Antimicrobial Peptides: De Novo Designed L- and D-Enantiomers Versus L- and D-LL37, Protein & Peptide Letters 2011; 18 (3) . https://dx.doi.org/10.2174/092986611794578288
DOI https://dx.doi.org/10.2174/092986611794578288 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cannabinoids and Schizophrenia: Therapeutic Prospects
Current Pharmaceutical Design Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials
Current Pharmaceutical Design Role of Lipopolysaccharides in Potential Applications of Nanocarrier Systems
Current Pharmaceutical Design Is There Still a Room for Azathioprine Monotherapy in Inflammatory Bowel Disease?
Current Drug Targets Molecular Pathways of Interferon-Stimulated Gene 15: Implications in Cancer
Current Protein & Peptide Science Immune Cell-derived Vesicles: Modulators and Mediators of Inflammation
Current Pharmaceutical Design Effects of Renal Replacement Therapy on Antimicrobial Therapy
Current Clinical Pharmacology Pentapeptides as Minimal Functional Units in Cell Biology and Immunology
Current Protein & Peptide Science Serial Extraction Technique of Rich Antibacterial Compounds in <i>Sargassum cristaefolium</i> Using Different Solvents and Testing their Activity
Current Bioactive Compounds Challenges Associated with Current and Future TB Treatment
Infectious Disorders - Drug Targets The Widespread Anti-Protozoal Action of HIV Aspartic Peptidase Inhibitors: Focus on Plasmodium spp., Leishmania spp. and Trypanosoma cruzi
Current Topics in Medicinal Chemistry Computer-aided Structural and Molecular Insights into the Mechanisms by which Pseudouridimycin (PUM) Disrupts Cleft Extension in Bacterial RNA Polymerase to Block DNA Entry and Exit
Letters in Drug Design & Discovery Seco-Tetracyclic and Seco-Pentacyclic Triterpenoids from Nature: Phytochemistry, Biological Activity: A Review
Mini-Reviews in Organic Chemistry A Comprehensive Review on the Biological and Pharmacological Activities of Rhodanine Based Compounds for Research and Development of Drugs
Mini-Reviews in Medicinal Chemistry Non-Enzymatic Protein Acetylation by 7-Acetoxy-4-Methylcoumarin: Implications in Protein Biochemistry
Protein & Peptide Letters Enhancing the Alternative Cellular Energy (ACE) Pathway with KELEA Activated Water as Therapy for Infectious Diseases
Infectious Disorders - Drug Targets Editorial (Thematic Issue: The Thoracic Space: An Amazing Pandora’s Box!)
Current Respiratory Medicine Reviews Strategies for Developing Tuberculosis Vaccines: Emerging Approaches
Current Drug Targets Indole Derivatives as Anti-Tubercular Agents: An Overview on their Synthesis and Biological Activities
Current Medicinal Chemistry Recent Patents for the Treatment of Asthma
Recent Patents on Inflammation & Allergy Drug Discovery